Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.

@article{Facchinetti2016TacklingAI,
  title={Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.},
  author={Francesco Facchinetti and M Tiseo and Massimo Di Maio and Paolo Graziano and Emilio Bria and G. C. Rossi and Silvia Novello},
  journal={Translational lung cancer research},
  year={2016},
  volume={5 3},
  pages={
          301-21
        }
}
Crizotinib is an oral inhibitor of anaplastic lymphoma kinase (ALK) with remarkable clinical activity in patients suffering from ALK-rearranged non-small cell lung cancer (NSCLC), accounting to its superiority compared to chemotherapy. Unfortunately, virtually all ALK-rearranged tumors acquire resistance to crizotinib, frequently within one year since the treatment initiation. To date, therapeutic strategies to overcome crizotinib resistance have focused on the use of more potent and… CONTINUE READING
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 124 REFERENCES

Alectinib in ALKpositive, crizotinib-resistant, non-small-cell lung cancer:a single-group, multicentre, phase 2 trial

  • AT Shaw, L Gandhi, S Gadgeel
  • Lancet Oncol ;17:234-42
  • 2016
Highly Influential
4 Excerpts

Clinical activity and safety of the ALK/ROS1 TKI inhibitor PF-06463922 in advanced NSCLC

  • T Bauer, BJ Solomon, B Besse
  • J Thor Oncol ;10:S239
  • 2015
Highly Influential
8 Excerpts

Similar Papers

Loading similar papers…